b
Thank You！
Your requirement has been sent, we will contact you quickly!
Sent Failed！
Try again!
Synonymous | (((R)-12-((S)-7,8-Difluoro-6,11-Dihydrodibenzo[b,e]Thiepin-11-yl)-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-1H-[1,4]Oxazino[3,4-c]Pyrido[2,1-f][1,2,4]Triazin-7-yl)oxy)Methyl Methyl Carbonate；({(12aR)-12-[(11S)-7,8-Difluoro-6,11-Dihydrodibenzo[b,e]Thiepin-11-yl]-6,8-Dioxo-3,4,6,8,12,12a-Hexahydro-1H-[1,4]Oxazino[3,4-c]Pyrido[2,1-f][1,2,4]Triazin-7-yl}oxy)Methyl Methyl Carbonate |
Structure |
|
CAS | 1985606-14-1 |
Molecular Formula | C27H23F2N3O7S |
Molecular Weight | 571.55 |
Appearance | White powder |
Packing | 25kg cardboard barrel |
Uses | New drugs for inhibiting the proliferation of influenza virus |
Storage | Sealed in dry,Store in freezer, under -20°C |
Baloxavir axetil is an innovative cap dependent endonuclease inhibitor. It is also one of the few new drugs in the world that can inhibit the proliferation of influenza virus.
Baloxavir axetil is a small molecule precursor drug. Its mechanism of action is different from the existing antiviral therapy. It can selectively inhibit cap dependent endonuclease and prevent polymerase function and influenza virus mRNA replication. The mechanism of action of existing anti influenza drugs is through targeting neuraminidase. Compared with these drugs, baloxavir targets an earlier stage of the viral replication cycle.
Baloxavir marboxil is a selective inhibitor of influenza virus CAP dependent endonuclease, which has been used in influenza A and B virus infection It shows therapeutic activity in preclinical models (including virus strains resistant to current antiviral agents). Baloxavir axetil was approved by FDA in 2018. It is a new anti influenza drug with new action mechanism. It can selectively inhibit cap dependent endonuclease and prevent polymerase function and influenza virus mRNA replication.
CRO
